Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P210006/S013

Thoraflex Hybrid

Vascutek, Ltd. · Decision date Jul 30, 2025

FDA DECISIONP210006/S013

What did the FDA decide?

FDA records P210006/S013 as a supplement to PMA P210006, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 30, 2025.

FDA approval order statement

change in the raw material supplier for the PTFE sheath used on the Thoraflex Hybrid delivery system
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Jul 30, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P210006/S013
Regulatory pathway
PMA supplement
Product code
QSK
Decision code
OK30
Decision date
Jul 30, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Hybrid stent graft, thoracic aortic lesion treatment.

Product code
QSK
FDA device class
3

For the original device and its historical approval scope, see PMA P210006. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P210006 · Original PMA

    Thoraflex Hybrid

  2. P210006/S013 received

    Application receipt date recorded by FDA.

  3. P210006/S013 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P210006. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P210006

Product / regulatory recordCompanyPathwayDecision dateSource
Vascutek, Ltd.PMA approvalApr 19, 2022FDA
Thoraflex HybridP210006/S014
Vascutek, Ltd.PMA supplementOct 16, 2025FDA
Thoraflex HybridP210006/S015
Vascutek, Ltd.PMA supplementOct 29, 2025FDA
Thoraflex HybridP210006/S016
Vascutek, Ltd.PMA supplementJan 29, 2026FDA
Thoraflex HybridP210006/S017
Vascutek, Ltd.PMA supplementApr 20, 2026FDA
Thoraflex HybridP210006/S019
Vascutek, Ltd.PMA supplementJun 24, 2026FDA
Thoraflex HybridP210006/S018
Vascutek, Ltd.PMA supplementSep 8, 2026FDA

Explore the linked device profile

Other records with product code QSK

Product / regulatory recordCompanyPathwayDecision dateSource
Artivion, IncPMA approvalJun 26, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Vascutek, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Newmains Ave., Inchinnan, PA49RR

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records